Piramal Pharma Q1 FY27 Revenue Rises 17% as Loss Narrows

Q1 performance sets the immediate context

Piramal Pharma Ltd reported revenue of ₹2,269.92 crore in the first quarter of FY27, representing year-on-year growth of 17.39%. The quarterly performance came after a difficult FY26, according to the July 30, 2026 result update cited in the available information. Revenue was lower by 17.51% sequentially from ₹2,751.77 crore in the preceding quarter. The company reported a net loss of ₹69.39 crore for the quarter. Separately reported Q1 FY27 information describes the loss as narrower than the ₹82 crore loss in Q1 FY26. The result therefore showed stronger annual revenue growth while profitability remained negative at the net level.

Revenue growth was broad-based across segments

The reported revenue growth was supported by all three operating businesses: contract development and manufacturing organisation, or CDMO; Complex Hospital Generics, or CHG; and India Consumer Healthcare. CDMO remained the largest segment, contributing 55% of sales in Q1 FY27. It reported revenue of ₹1,187 crore, up 19% year-on-year. CHG accounted for 30% of sales and recorded ₹743 crore in revenue, an increase of 17%. India Consumer Healthcare represented 15% of sales, with revenue of ₹347 crore and growth of approximately 15%.

Operating profit improved from a year earlier

Operating profit was ₹195.20 crore in Q1 FY27. This was 82.94% higher year-on-year, based on the supplied quarterly summary. However, it was 31.45% lower than ₹284.74 crore in the immediately preceding quarter. PBDT stood at ₹216.09 crore, up 82.72% year-on-year but down 17.33% quarter-on-quarter from ₹261.38 crore. These movements show that the year-on-year improvement in operations did not translate into sequential growth from the prior quarter.

Profit before tax moved into a loss

Profit before tax was a loss of ₹7.46 crore in Q1 FY27, compared with a profit before tax of ₹43 crore in the previous quarter. The supplied summary describes this as a 117.35% quarter-on-quarter decline. The same data indicates 90.56% year-on-year growth, though the quarter still ended with a pre-tax loss. At the net level, the reported ₹69.39 crore loss was substantially wider than the ₹8.83 crore loss in the prior quarter. Investors assessing the quarter will therefore have to distinguish between the improvement in revenue and operating profit from a year ago and the continued losses after other costs and taxes.

CDMO order activity remains a key operating factor

The cited result update said improving biopharma funding was leading to stronger requests for proposals and an increase in CDMO order inflows. This is relevant because CDMO generated more than half of Piramal Pharma's Q1 FY27 sales. Higher capacity utilisation and operating leverage were identified as factors that could support margins during FY27. The company has also prioritised organic expansion, according to the available report. No quantified guidance for segment profitability was provided in the supplied material.

CHG and consumer healthcare contributed to growth

Demand in selected markets outside the US supported the CHG business, including traction in ex-US inhalation anaesthesia. Management expected Kenalog supplies to begin in Q2 FY27, which was identified as a potential support for CHG growth. Consumer healthcare continued to grow, with approximately 15% year-on-year revenue growth in Q1. Together, these trends point to a more diversified revenue contribution rather than reliance on a single business line. But the supplied information does not provide a segment-wise profit breakdown.

Q2 FY27 reporting is in focus

The September-quarter period for Q2 FY27 runs from July 1, 2026 to September 30, 2026. Piramal Pharma was listed among companies scheduled to announce second-quarter results on October 27, 2026. The company has also scheduled a conference call on October 28, 2026, from 10:00 am to 10:45 am IST, to discuss Q2 and first-half FY27 financial results. Earlier information stated that the Q2 results date had not been confirmed as of September 15, 2026. It also noted that November 14, 2026 was the statutory outer deadline for publishing the September-quarter results, rather than an expected announcement date.

The Q2 comparison base is defined by reported figures

For the September 2025 quarter, Piramal Pharma reported revenue of ₹2,044 crore and a net loss of ₹99 crore, according to the supplied preview. These are the key year-on-year comparison points for the Q2 FY27 release. No verified public analyst consensus estimate for Q2 FY27 revenue or profit was available in the material provided. As a result, there is no supported basis for assigning a forecast figure to the upcoming quarter. The Q1 operating margin of 9.0% was identified as another metric to watch, along with any exceptional items disclosed with the results.

What the numbers mean for investors

Piramal Pharma's Q1 figures indicate that sales growth returned across CDMO, CHG and consumer healthcare, while operating profit increased sharply from the year-earlier period. The sequential declines in revenue and operating profit, along with the net loss, show that the recovery was not uniform across all financial measures. The next result announcement will provide updated evidence on CDMO order activity, the start of Kenalog supplies, capacity utilisation and margin performance. The October 28 conference call is the confirmed next event cited in the available information, where management is scheduled to discuss Q2 and H1 FY27 results.